Hemostemix (TSE:HEM) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Hemostemix Inc. has entered into a manufacturing partnership with CytoImmune Therapeutics to produce ACP-01, a cell therapy for severe arterial diseases, in a cutting-edge facility in Puerto Rico. Additionally, Hemostemix has secured $1.8 million in financing, with CytoImmune investing $1.37 million, signifying a strong commitment to the advancement of cell therapy. This strategic move aims to increase production and sales, offering a lifeline to patients facing chronic pain and potential limb amputation.
For further insights into TSE:HEM stock, check out TipRanks’ Stock Analysis page.